Betaferon™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Betaferon is indicated for the treatment of: - Ambulatory patients with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - Betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - The treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (MRI) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Source: ARTG

• Shelf lifetime is 24 Months
• Store below 30 degrees Celsius

Source: ARTG

Composite pack

This medicine is a pack that contains more than one component.

Important: The components listed below are not necessarily in order of use. Please refer to the Consumer Medicine Information (CMI) or consult your doctor for proper administration instructions and sequence.

Component

• Injection, powder for
• Subcutaneous
• WHITE TO OFF WHITE CAKE OR POWDER.

Component

• Diluent, not applicable
• Subcutaneous
• DILUENT: CLEAR, COLOURLESS SOLUTION. RECONSTITUTED SOLUTION: COLOURLESS TO LIGHT YELLOW SOLUTION.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 15 x 0.25mg powder for injection vials with 1.2mL diluent syringes

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item code 8101J (Opens in new tab). Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: interferon beta-1b

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).